
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...





